The global Milbexime Anthelmintic Market is on a robust growth trajectory, driven by the escalating prevalence of parasitic infections in both companion animals and livestock, coupled with a growing global focus on animal health and welfare. According to a comprehensive report by Wise Guy Reports, the market was valued at USD 600 million in 2024. It is projected to grow from USD 600 million in 2025 to USD 1,200 million by 2035, registering a Compound Annual Growth Rate (CAGR) of 7.1% during the forecast period. This steady expansion reflects the critical role anthelmintics play in ensuring animal health, food safety, and the sustainability of livestock operations worldwide.

Milbexime is a broad-spectrum anthelmintic agent primarily used in veterinary medicine to combat internal parasites such as roundworms, hookworms, and whipworms in companion animals, as well as a range of gastrointestinal nematodes in livestock. Its efficacy, safety profile, and ease of administration make it a cornerstone of modern parasite control programs. The market's growth is underpinned by several powerful drivers. First, the increasing prevalence of parasitic infections is a primary factor. The World Health Organization notes the significant global burden of zoonotic diseases, many of which originate from parasitic infections in animals. As awareness of these risks grows, both veterinarians and pet owners are prioritizing preventive deworming programs, driving consistent demand for effective anthelmintics like Milbexime.

Second, the rise in pet ownership and companion animal care is a significant market catalyst. Globally, the trend of humanizing pets has led to increased spending on their health and well-being. Pet owners are increasingly seeking comprehensive parasite protection for their dogs and cats, viewing it as an essential part of responsible pet ownership. This shift is particularly pronounced in developed regions like North America and Europe, where companion animal care represents a substantial portion of the market. In emerging economies, a growing middle class is similarly investing more in the health of their animal companions.

Third, the expansion of the livestock sector to meet global food demands is driving demand for anthelmintics. Parasitic infections in cattle, sheep, and pigs can lead to significant economic losses through reduced weight gain, decreased milk production, and increased mortality. As the global population grows and the demand for animal protein rises, farmers are adopting more intensive production systems, which in turn necessitates robust parasite management strategies. Regulatory bodies and agricultural organizations are emphasizing the importance of effective anthelmintics to maintain productivity and ensure food safety, creating a stable and growing market for Milbexime. With technological advancements in drug formulation and delivery systems enhancing treatment efficacy and compliance, the Milbexime anthelmintic market is poised for sustained, healthy growth.